AU2013229779B2 - Compositions, methods, and kits for regulating energy metabolism - Google Patents

Compositions, methods, and kits for regulating energy metabolism Download PDF

Info

Publication number
AU2013229779B2
AU2013229779B2 AU2013229779A AU2013229779A AU2013229779B2 AU 2013229779 B2 AU2013229779 B2 AU 2013229779B2 AU 2013229779 A AU2013229779 A AU 2013229779A AU 2013229779 A AU2013229779 A AU 2013229779A AU 2013229779 B2 AU2013229779 B2 AU 2013229779B2
Authority
AU
Australia
Prior art keywords
composition
leucine
subject
compositions
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013229779A
Other languages
English (en)
Other versions
AU2013229779A1 (en
Inventor
E. Douglas Grindstaff Ii
Michael ZEMEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nusirt Sciences Inc
Original Assignee
Nusirt Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nusirt Sciences Inc filed Critical Nusirt Sciences Inc
Publication of AU2013229779A1 publication Critical patent/AU2013229779A1/en
Application granted granted Critical
Publication of AU2013229779B2 publication Critical patent/AU2013229779B2/en
Priority to AU2018200861A priority Critical patent/AU2018200861A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicinal Preparation (AREA)
  • Tea And Coffee (AREA)
AU2013229779A 2012-03-08 2013-03-08 Compositions, methods, and kits for regulating energy metabolism Ceased AU2013229779B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018200861A AU2018200861A1 (en) 2012-03-08 2018-02-06 Compositions, methods, and kits for regulating energy metabolism

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261608595P 2012-03-08 2012-03-08
US61/608,595 2012-03-08
US201261656407P 2012-06-06 2012-06-06
US61/656,407 2012-06-06
US13/662,345 US9198454B2 (en) 2012-03-08 2012-10-26 Compositions, methods, and kits for regulating energy metabolism
US13/662,345 2012-10-26
PCT/US2013/030044 WO2013134736A1 (en) 2012-03-08 2013-03-08 Compositions, methods, and kits for regulating energy metabolism

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018200861A Division AU2018200861A1 (en) 2012-03-08 2018-02-06 Compositions, methods, and kits for regulating energy metabolism

Publications (2)

Publication Number Publication Date
AU2013229779A1 AU2013229779A1 (en) 2014-10-23
AU2013229779B2 true AU2013229779B2 (en) 2017-11-09

Family

ID=49114651

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013229779A Ceased AU2013229779B2 (en) 2012-03-08 2013-03-08 Compositions, methods, and kits for regulating energy metabolism
AU2018200861A Abandoned AU2018200861A1 (en) 2012-03-08 2018-02-06 Compositions, methods, and kits for regulating energy metabolism

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018200861A Abandoned AU2018200861A1 (en) 2012-03-08 2018-02-06 Compositions, methods, and kits for regulating energy metabolism

Country Status (7)

Country Link
US (4) US9198454B2 (enExample)
EP (1) EP2822579B1 (enExample)
JP (2) JP6210517B2 (enExample)
AU (2) AU2013229779B2 (enExample)
CA (1) CA2866718C (enExample)
HK (1) HK1205942A1 (enExample)
WO (1) WO2013134736A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
SG10201709195TA (en) 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
CN105228627B (zh) 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
KR20160119863A (ko) 2014-02-27 2016-10-14 뉴서트 사이언시스, 인크. 간 지방증의 감소 또는 예방을 위한 조성물 및 방법
US20180235917A1 (en) * 2014-09-24 2018-08-23 Nusirt Sciences, Inc. Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
WO2017040407A1 (en) * 2015-09-01 2017-03-09 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash)
JP6250196B2 (ja) * 2015-10-30 2017-12-20 恭正 加藤 糖尿病治療用組成物
US11701336B2 (en) 2015-10-30 2023-07-18 Yasumasa Kato Method of determining composition effective for treating diabetes
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
IT201700087376A1 (it) * 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
MX2020001765A (es) 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica.
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
IT201800006725A1 (it) 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
US10568352B1 (en) 2018-10-25 2020-02-25 Wiser Concepts, LLC Nutritional compositions and methods of treatment therewith
IT201900002109A1 (it) 2019-02-13 2020-08-13 Professional Dietetics Spa Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
JP7795755B2 (ja) * 2020-04-17 2026-01-08 共栄化学工業株式会社 皮膚外用剤
CN112056272A (zh) * 2020-09-16 2020-12-11 华中农业大学 一种评价甜味剂摄入对小鼠影响的方法
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
KR20250159205A (ko) * 2023-03-03 2025-11-10 그래즈 이노베이션 지방산의 강화된 대사성 산화를 위한 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120983A1 (en) * 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
US20080233245A1 (en) * 2007-03-19 2008-09-25 Lesley Joan White Liquid nutrient composition for improving performance

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810994A (en) 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5087624A (en) 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US5886012A (en) 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5419283A (en) 1992-04-08 1995-05-30 Ciuffo Gatto S.R.L. Animal chew toy of starch material and degradable ethylene copolymer
JP3219838B2 (ja) 1992-05-12 2001-10-15 沖電気工業株式会社 半導体素子の製造方法
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
LU88369A1 (fr) 1993-07-12 1994-04-01 Michel Urso Prof Medecin Et Ch Acides aminés à chaînes ramifiées
US5339771A (en) 1993-09-15 1994-08-23 Axelrod Herbert R Animal chew toy containing animal meal
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5616569A (en) 1994-03-28 1997-04-01 The Iams Company Pet food product containing fermentable fibers and process for treating gastrointestinal disorders
US6048903A (en) 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
ATE245999T1 (de) 1996-01-09 2003-08-15 Riken Aminosäurezusammensetzungen
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
IT1291113B1 (it) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
GB9723059D0 (en) 1997-10-31 1998-01-07 Mars Uk Ltd Pet food
EP1075481A1 (en) 1998-05-04 2001-02-14 Andreas Johannes Kesel Monomeric, oligomeric and polymeric knoevenagel condensation products
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
PT1140012E (pt) 1998-12-17 2004-05-31 Alza Corp Conversao de capsulas de gelatina cheias com liquido em sistemas de libertacao controlada por camadas multiplas
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
CA2366602A1 (en) 1999-03-08 2000-09-14 Medicure Inc. Pyridoxal analogues for vitamin b-6 disorders
FR2790645B1 (fr) 1999-03-12 2001-06-08 Arkopharma Laboratoires Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols
WO2001021165A1 (en) 1999-09-21 2001-03-29 Rutgers, The State University Resveratrol analogs for prevention of disease
US6527711B1 (en) 1999-10-18 2003-03-04 Bodymedia, Inc. Wearable human physiological data sensors and reporting system therefor
US6280779B1 (en) 1999-12-28 2001-08-28 Colgate-Palmolive Company Pet food for maintaining normal bowel health
US7261690B2 (en) 2000-06-16 2007-08-28 Bodymedia, Inc. Apparatus for monitoring health, wellness and fitness
BRPI0414359A (pt) 2000-06-16 2006-11-14 Bodymedia Inc sistema para a monitoração e gerenciamento do peso corpóreo e demais condições psicológicas que abrangem um planejamento interativo e personalizado, intervenção e capacidade de formular relatórios
US6605038B1 (en) 2000-06-16 2003-08-12 Bodymedia, Inc. System for monitoring health, wellness and fitness
US7689437B1 (en) 2000-06-16 2010-03-30 Bodymedia, Inc. System for monitoring health, wellness and fitness
US6384087B1 (en) 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
DE60039726D1 (de) 2000-12-29 2008-09-11 Martin Francis Gannon Tiernahrungsmittelzusammensetzung
EA006429B1 (ru) 2001-03-09 2005-12-29 Сосьете Де Продюи Нестле С.А. Композиция для предупреждения или восстановления возрастных функциональных дефицитов у млекопитающих и способ ее применения
US6338862B1 (en) 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
US6595929B2 (en) 2001-03-30 2003-07-22 Bodymedia, Inc. System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow
EP1525323B1 (en) 2001-11-09 2015-01-21 Dana-Farber Cancer Institute, Inc. Pgc-1beta, a novel pgc-1 homologue and uses therefor
US20030187055A1 (en) 2002-02-25 2003-10-02 Riker Donald K. Synergistic pharmaceutical combinations for treating obesity
EP3173082A1 (en) 2002-05-17 2017-05-31 Duke University Method for treating obesity
DE60317225T2 (de) 2002-06-26 2008-05-29 Intarcia Therapeutics, Inc., Emeryville Minimal nachgiebiger volumen-effizienter kolben für osmotische medikamentenabgabesysteme
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
US7020508B2 (en) 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
KR20050055072A (ko) 2002-10-09 2005-06-10 보디미디어 인코퍼레이티드 인체의 생리 및 컨텍스츄얼 정보를 검출, 수신, 유도 및디스플레이하는 장치
US20050064070A1 (en) 2002-10-11 2005-03-24 Jeffrey Liebrecht Beverage compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US7744930B2 (en) * 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
US7288570B2 (en) 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
AU2004221875B2 (en) 2003-03-13 2010-11-11 Vector Usa Inc. A film having a liquid absorbed therein
US20040186046A1 (en) 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
MXPA05009933A (es) 2003-03-18 2005-11-04 Novartis Ag Composiciones que comprenden acidos grasos y aminoacidos.
US7160565B2 (en) 2003-03-31 2007-01-09 Breakthru Products, Llc Hydration beverage and method of delivering nutrients
ATE390142T1 (de) 2003-05-14 2008-04-15 Indus Biotech Pvt Ltd Synergistische zusammensetzung zur behandlung von diabetes mellitus
WO2005003766A2 (en) 2003-06-13 2005-01-13 Whitehead Institute For Biomedical Research Methods of regulating metabolism and mitochondrial function
AU2004257756A1 (en) 2003-07-10 2005-01-27 Carl A. Forest Foods, beverages, condiments, spices and salad dressings with specialized supplements
JP2005097273A (ja) * 2003-08-19 2005-04-14 Toyo Shinyaku:Kk 運動能力向上組成物
BRPI0414345A (pt) 2003-09-12 2006-11-07 Bodymedia Inc método e aparelho para medição de parámetros relacionados com o coração
US7495101B2 (en) 2003-11-19 2009-02-24 Dsm Ip Assets B.V. Manufacture of vitamin B6
JPWO2005049006A1 (ja) 2003-11-21 2007-11-29 味の素株式会社 糖尿病治療剤
CA2546286C (en) 2003-11-26 2012-10-02 Hill's Pet Nutrition, Inc. Method to reduce odor of excreta from companion animals
DE602004016385D1 (de) * 2003-12-24 2008-10-16 Nutricia Nv Zusammensetzungen mit pantothensäure oder derivaten davon und ihre verwendung zur stimulierung des appetits
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20050171027A1 (en) 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US20050215882A1 (en) 2004-03-23 2005-09-29 The Regents Of The University Of Michigan Noninvasive method to determine fat content of tissues using MRI
EA011446B1 (ru) 2004-06-17 2009-02-27 Форест Лэборэтериз, Инк. Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
WO2006001278A1 (ja) 2004-06-28 2006-01-05 Kao Corporation Ａｍｐｋ活性化剤
CN101106997A (zh) 2004-08-17 2008-01-16 约翰·霍普金斯大学 Pde5抑制剂组合物及治疗心脏病征候的方法
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20080004335A1 (en) 2004-11-29 2008-01-03 Kinya Takagaki Athletic Ability Enhancing Composition
US20060115555A1 (en) 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplements containing xanthone extracts
EP1853610A1 (en) 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
EP1898890A1 (en) 2005-06-16 2008-03-19 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
DK1910384T3 (da) 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
WO2007041643A1 (en) 2005-10-03 2007-04-12 University Of Tennessee Research Foundation Dietary calcium for reducing the production of reactive oxygen species
JP2007161675A (ja) * 2005-12-16 2007-06-28 Taisho Pharmaceut Co Ltd 疲労改善内服剤
AU2007204692B2 (en) 2006-01-10 2011-06-02 Hill's Pet Nutrition, Inc. Compositions and method for promoting fat loss
EP1996215A2 (en) 2006-02-28 2008-12-03 Trustees Of Boston University Metabolic regulators and uses thereof
US7691388B2 (en) 2006-03-24 2010-04-06 Ocean Nutrition Canada Limited Compositions comprising Porphyra and methods of making and using thereof
BRPI0710584A2 (pt) 2006-04-05 2011-08-16 Chemaphor Inc suplemento de dieta contendo carotenóide
JP2007306851A (ja) * 2006-05-18 2007-11-29 仁 ▲吉▼井 食塩組成物およびその製造方法
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
US20090291958A1 (en) 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
MX2009000385A (es) 2006-07-12 2009-04-06 Univ Tennessee Res Foundation Acil-anilidas sustituidas y metodos de uso de las mismas.
JP2008063328A (ja) 2006-08-07 2008-03-21 Kowa Co 糸球体疾患治療剤
JP5507802B2 (ja) 2006-08-10 2014-05-28 花王株式会社 筋肉老化抑制剤
US20080187928A1 (en) 2006-12-29 2008-08-07 The Salk Institute For Biological Studies Methods for enhancing exercise performance
ES2660173T3 (es) 2007-01-16 2018-03-21 Ipintl, Llc Nueva composición para el tratamiento del síndrome metabólico
US8275635B2 (en) 2007-02-16 2012-09-25 Bodymedia, Inc. Integration of lifeotypes with devices and systems
US8597677B2 (en) 2007-02-23 2013-12-03 Hill's Pet Nutrition, Inc. Compositions and methods for controlling the weight of animals
US20080233244A1 (en) 2007-03-23 2008-09-25 Solae, Llc Animal food compositions and treats
WO2008119070A1 (en) 2007-03-28 2008-10-02 Trustees Of Boston University Methods of treatment using sirt modulators and compositions containing sirt1 modulators
US20080268038A1 (en) * 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
US20080286254A1 (en) 2007-05-17 2008-11-20 Kaneka Corporation Composition comprising licorice polyphenol
WO2008153945A2 (en) 2007-06-06 2008-12-18 University Of South Florida Nutraceutical co-crystal compositions
WO2008157537A2 (en) 2007-06-19 2008-12-24 Ironwood Pharmaceuticals, Inc Compositions and methods of use for treating or preventing lipid related disorders
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US7989007B2 (en) 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
JP5550077B2 (ja) 2007-09-07 2014-07-16 ナイキ インターナショナル リミテッド 運動機能性を有する装着可能な装置アセンブリ
WO2009054994A2 (en) 2007-10-23 2009-04-30 President And Fellows Of Harvard College Sirt-3 related methods and compositions for mimicking exercise
US20090156648A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (HICA)
CA2714181C (en) 2008-02-04 2013-12-24 Mercury Therapeutics, Inc. Ampk modulators
CN101978374A (zh) 2008-03-03 2011-02-16 耐克国际有限公司 交互式运动设备系统
EP2700434A3 (en) 2008-04-02 2014-07-02 Nike International Ltd. Wearable device assembly having athletic functionality
GB0809665D0 (en) 2008-05-28 2008-07-02 Mars Uk Ltd Food product
WO2010004982A1 (ja) 2008-07-07 2010-01-14 持田製薬株式会社 脂質異常症の改善または治療薬
US8835490B2 (en) 2008-08-15 2014-09-16 Nestec Sa Methods for enhancing energy metabolism
RU2011115184A (ru) 2008-09-19 2012-10-27 Нестек С.А. (Ch) Питательная поддержка для предупреждения или ослабления паралича костного мозга или нейтропении во время противораковой терапии
CN102300578A (zh) 2008-12-01 2011-12-28 延寿有限责任公司 用于改变健康、安康和寿命的方法和组合物
CA2929927C (en) 2009-04-26 2018-09-11 Nike Innovate C.V. Gps features and functionality in an athletic watch system
BRPI0904259A2 (pt) 2009-05-06 2012-02-28 Provets-simões Laboratório Ltda suplemento alimentar para pássaros em fase reprodutiva
EP2448413A4 (en) 2009-07-01 2013-02-13 Magceutics Inc SLOW RELEASE MAGNESIUM COMPOSITION AND USES THEREOF
US8691303B2 (en) 2009-07-31 2014-04-08 The Iams Company Dusted animal food
US20110064720A1 (en) 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
US20110070258A1 (en) 2009-09-18 2011-03-24 Polifenoles Naturales, S.L. Method of slowing the aging process by activating sirtuin enzymes
WO2011051974A1 (en) 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
US8173181B2 (en) 2009-11-09 2012-05-08 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
WO2011087708A1 (en) 2010-01-13 2011-07-21 Dodds W Jean Animal food compositions for promoting liver cleansing and mitigations of intestinal dysbiosis
CN102753183A (zh) 2010-02-03 2012-10-24 花王株式会社 运动功能改善剂
US20110208153A1 (en) 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
US20120058088A1 (en) 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
CN102077936B (zh) * 2010-09-20 2013-04-24 王强 一种糖尿病患者专用的海洋特膳食品
US9167991B2 (en) 2010-09-30 2015-10-27 Fitbit, Inc. Portable monitoring devices and methods of operating same
WO2012060884A1 (en) 2010-11-04 2012-05-10 Nestec S.A. Methods and compositions for preventing and treating osteoarthritis
EP2661266B1 (en) 2011-01-07 2020-09-16 Anji Pharma (US) LLC Chemosensory receptor ligand-based therapies
WO2012097064A1 (en) 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
US20120231087A1 (en) 2011-03-07 2012-09-13 Olympic Seafood Compositions And Methods for Nutritional Supplementation
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
JP2016516405A (ja) 2013-03-15 2016-06-09 ニューサート サイエンシーズ， インコーポレイテッド ペットの処置のための組成物、方法、およびキット
KR20160119863A (ko) 2014-02-27 2016-10-14 뉴서트 사이언시스, 인크. 간 지방증의 감소 또는 예방을 위한 조성물 및 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120983A1 (en) * 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
US20080233245A1 (en) * 2007-03-19 2008-09-25 Lesley Joan White Liquid nutrient composition for improving performance

Also Published As

Publication number Publication date
EP2822579A1 (en) 2015-01-14
AU2018200861A1 (en) 2018-02-22
HK1205942A1 (en) 2015-12-31
JP2018012722A (ja) 2018-01-25
JP6210517B2 (ja) 2017-10-11
CA2866718C (en) 2019-06-18
US20170000777A1 (en) 2017-01-05
US20170368045A1 (en) 2017-12-28
EP2822579B1 (en) 2019-06-26
CA2866718A1 (en) 2013-09-12
US20130237605A1 (en) 2013-09-12
EP2822579A4 (en) 2015-10-28
US9408410B2 (en) 2016-08-09
US9713609B2 (en) 2017-07-25
WO2013134736A1 (en) 2013-09-12
JP2015510888A (ja) 2015-04-13
AU2013229779A1 (en) 2014-10-23
US20160113317A1 (en) 2016-04-28
US9198454B2 (en) 2015-12-01
US9901573B2 (en) 2018-02-27

Similar Documents

Publication Publication Date Title
AU2013229779B2 (en) Compositions, methods, and kits for regulating energy metabolism
US10383837B2 (en) Compositions and methods for modulating metabolic pathways
US9724319B2 (en) Compositions and methods for the reduction or prevention of hepatic steatosis
US20160279130A1 (en) Compositions and methods for increasing energy metabolism
WO2018085440A1 (en) Reduction and prevention of muscle loss by conjugated linoleic acid (cla) and vitamin d

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired